This study is currently recruiting participants.
Verified by Merck, June 2010
A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™
This study will evaluate whether V503, a multivalent HPV vaccine, is well-tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™
View the entire study here.